Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions Saved Articles My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in EuropeAuthor of the article: You can save this article by registering for free here. Or sign-in if you have an account.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountAdvances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology.Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet® franchise.Expands footprint by adding Canada and Japan; strengthens presence in Europe, with direct operations in 18 countries, with 265 employees. Adds approximately €190 million in 2025 revenue.Financial terms of the transaction are not disclosed.BOLOGNA, Italy & MILAN, Italy — Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. (“SEVER”) for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againThe acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet® methotrexate franchise, to Alfasigma’s rheumatology portfolio, which includes the Jyseleca® franchise. It will also deepen Alfasigma’s commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to rheumatology, the acquisition includes Nordic Pharma’s portfolio in women’s health, critical care and ophthalmology. It also brings 265 employees with specialist capabilities and expertise.The transaction is subject to customary closing conditions, including any requiredregulatory agency clearances.The transaction supports Alfasigma’s M&A-led growth strategy as it actively expands its international specialty and rare business, with a focus on gastroenterology and immunology. It follows recent portfolio-building initiatives, including the acquisition of Jyseleca® in inflammatory diseases and the licensing agreement with GSK for linerixibat for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients.Francesco Balestrieri, Chief Executive Officer, Alfasigma, said:“Alfasigma is pursuing a deliberate strategy to identify the right opportunities to build our global specialty and rare disease business, focused on areas of significant unmet need in gastroenterology and immunology. The acquisition of Nordic Pharma marks a decisive step forward in that journey, strengthening our European presence and expanding our rheumatology portfolio. By combining our portfolios, scientific expertise and talented teams, we are better positioned to deliver meaningful innovation and value for patients and shareholders.”Charlotte Phelps, Chief Executive Officer, Nordic Group B.V., commented:“Alfasigma is the right partner for Nordic Pharma as we enter our next phase of growth. Both companies are patient-focused, rooted in science and entrepreneurial. We look forward to combining our experience to support patients.”Forward looking statementsThis press release contains forward‑looking statements. Actual results may differ materially due to various risks and uncertainties, including regulatory outcomes and market conditions.Alfasigma is a privately owned, medium-sized, global pharmaceutical company, headquartered in Italy with offices in Bologna and Milan. Its products are distributed in more than 100 markets worldwide. The company employs approximately 4,000 people. Alfasigma continues to expand its international presence and portfolio through acquisitions, partnerships, and licensing agreements. Its portfolio ranges from consumer healthcare products and primary care treatments to specialty and rare disease medications, with key therapeutic focus on gastroenterology, immunology, and vascular health. Visit www.alfasigma.com.About Jyseleca® (filgotinib)Approved for use as a second-line treatment in inflammatory and autoimmune diseases including rheumatoid arthritis and ulcerative colitis. Jyseleca is marketed by Alfasigma in EU and EEA countries and in the UK.About SEVER Life Sciences B.V.SEVER Life Sciences B.V. is an international life sciences group with activities spanning pharmaceutical development, manufacturing and specialty pharmaceuticals. Following completion, SEVER will continue to focus on the development of its remaining businesses, namely Sever Pharma Solutions AB, Farmaprim S.R.L., Esperante Development B.V. and Nordic Pharma Inc.Nordic Group B.V. is an international specialty pharmaceutical company headquartered in Hoofddorp, The Netherlands, with a diversified portfolio of branded and niche pharmaceutical products marketed across Europe and selected international markets. Visit www.nordicpharma.com.View source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.